ArticleMedicine2026
The clinical pathological significance of ILK and FABP4 protein expression in EHCC.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the clinical and pathological significance of integrin-linked kinase (ILK) and fatty acid-binding protein 4 (FABP4) expression in EHCC. We utilized EnVision immunohistochemistry technology to assess the expression levels of ILK and FABP4 in 100 cases of patients with EHCC. Data analysis was conducted using SPSS version 26.0 (Chicago). The proteins ILK and FABP4 exhibited elevated expression levels in extrahepatic cholangiocarcinoma (EHCC) tumors when compared to peritumoral tissues, adenomas, and normal biliary tract tissues, with statistical significance noted (P <.05 or P <.01). A significant positive correlation was identified between the expressions of ILK and FABP4 in EHCC (P <.01). Kaplan-Meier survival analysis demonstrated that EHCC patients with positive expression of ILK and/or FABP4 had significantly reduced survival times in comparison to those with negative expression (P = .000). Additionally, Cox multivariate analysis indicated that positive expressions of ILK and/or FABP4 serve as independent prognostic factors associated with poor outcomes in EHCC patients. The area under the curve for ILK was calculated to be 0.687 (95% CI: 0.600-0.773), while for FABP4, it was 0.638 (95% CI: 0.548-0.728). The current research demonstrates that the positive expression of ILK and FABP4 is significantly linked to the pathogenesis, clinical manifestations, pathological characteristics, biological behaviors, and unfavorable prognosis in EHCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.